Bristol-Myers Squibb (BMY) ROE: History & Chart

Bristol-Myers Squibb Company(BMY)

Drug Manufacturers - General · Princeton, NJ

$63.70-0.40 (-0.62%)

Delayed quote: Sep 15, 2026, 3:05 PM EDT

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ

32,500 employees

www.bms.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher Boerner

View full financials

BMY Return on Equity (ROE) Metrics

RETURN ON EQUITY (ROE)

41.59%

RETURN ON EQUITY (ROE) AVG TTM

35.51%

RETURN ON EQUITY (ROE) AVG 3Y

8.97%

RETURN ON EQUITY (ROE) AVG 5Y

10.08%

RETURN ON EQUITY (ROE) AVG 10Y

15.55%

RETURN ON EQUITY (ROE) AVG 15Y

18.33%

RETURN ON EQUITY (ROE) AVG 20Y

21.14%

CURRENT VS TTM AVG

+17.13%

CURRENT VS 3Y AVG

+363.68%

CURRENT VS 5Y AVG

+312.72%

CURRENT VS 10Y AVG

+167.53%

CURRENT VS 15Y AVG

+126.86%

CURRENT VS 20Y AVG

+96.70%

SECTOR MEDIAN · HEALTHCARE

13.01%

median of 84 covered companies

CURRENT VS SECTOR MEDIAN

+219.66%

vs the sector median at left

NAME	MARKET CAP	RETURN ON EQUITY (ROE)	TTM	3Y	5Y
Bristol-Myers Squibb Company (BMY)	$130.12B	41.59%	35.51%	8.97%	10.08%
Vertex Pharmaceuticals Incorporated (VRTX)vs ›	$130.09B	21.76%	8.96%	15.60%	19.47%
Intuitive Surgical, Inc. (ISRG)vs ›	$133.10B	17.28%	15.07%	13.91%	13.46%
CVS Health Corp. (CVS)vs ›	$120.82B	6.16%	4.23%	6.35%	7.74%
Medtronic plc (MDT)vs ›	$120.31B	10.41%	9.71%	8.51%	8.44%
Danaher Corporation (DHR)vs ›	$146.73B	7.61%	7.38%	9.51%	10.24%
Stryker Corporation (SYK)vs ›	$108.02B	15.55%	14.50%	15.05%	14.30%
McKesson Corporation (MCK)vs ›	$105.21B	N/A	-189.06%	-180.53%	3473.86%
Pfizer Inc. (PFE)vs ›	$156.88B	5.09%	9.04%	13.32%	16.07%
Sanofi (SNY)vs ›	$102.33B	5.82%	9.06%	9.15%	10.86%

NAME

MARKET CAP

RETURN ON EQUITY (ROE)

TTM

Bristol-Myers Squibb Company (BMY)

$130.12B

41.59%

35.51%

8.97%

10.08%

Vertex Pharmaceuticals Incorporated (VRTX)vs ›

$130.09B

21.76%

8.96%

15.60%

19.47%

Intuitive Surgical, Inc. (ISRG)vs ›

$133.10B

17.28%

15.07%

13.91%

13.46%

CVS Health Corp. (CVS)vs ›

$120.82B

6.16%

4.23%

6.35%

7.74%

Medtronic plc (MDT)vs ›

$120.31B

10.41%

9.71%

8.51%

8.44%

Danaher Corporation (DHR)vs ›

$146.73B

7.61%

7.38%

9.51%

10.24%

Stryker Corporation (SYK)vs ›

$108.02B

15.55%

14.50%

15.05%

14.30%

McKesson Corporation (MCK)vs ›

$105.21B

N/A

-189.06%

-180.53%

3473.86%

Pfizer Inc. (PFE)vs ›

$156.88B

5.09%

9.04%

13.32%

16.07%

Sanofi (SNY)vs ›

$102.33B

5.82%

9.06%

9.15%

10.86%

Return on Equity (ROE) FAQ

What is the return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?

The return on equity (ROE) for BMY stock is 41.59%.

Is Bristol-Myers Squibb Company's return on equity (ROE) high or low?

The return on equity (ROE) of 41.59% is 313% above its 5-year average of 10.08%, near the high end of its 5-year range (-54.78%–41.59%).

What is the TTM average return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?

The TTM average return on equity (ROE) for BMY stock is 35.51%.

What is the 3Y average return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?

The 3Y average return on equity (ROE) for BMY stock is 8.97%.

What is the 5Y average return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?

The 5Y average return on equity (ROE) for BMY stock is 10.08%.

What is the 10Y average return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?

The 10Y average return on equity (ROE) for BMY stock is 15.55%.

What is the 15Y average return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?

The 15Y average return on equity (ROE) for BMY stock is 18.33%.

What is the 20Y average return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?

The 20Y average return on equity (ROE) for BMY stock is 21.14%.

DATE	RETURN ON EQUITY (ROE)
2026-06-30	41.59%
2026-03-31	36.25%
2025-12-31	38.19%
2025-09-30	32.55%
2025-06-30	28.96%
2025-03-31	31.16%
2024-12-31	-54.78%
2024-09-30	-42.34%
2024-06-30	-38.44%
2024-03-31	-37.28%
2023-12-31	27.27%
2023-09-30	28.57%
2023-06-30	24.91%
2023-03-31	22.97%
2022-12-31	20.37%
2022-09-30	20.44%
2022-06-30	20.30%
2022-03-31	19.79%
2021-12-31	19.46%
2021-09-30	-14.52%
2021-06-30	-13.80%
2021-03-31	-16.54%
2020-12-31	-23.84%
2020-09-30	-0.09%
2020-06-30	-1.15%
2020-03-31	1.91%
2019-12-31	6.66%
2019-09-30	32.04%
2019-06-30	38.65%
2019-03-31	33.80%
2018-12-31	35.07%
2018-09-30	10.50%
2018-06-30	3.05%
2018-03-31	7.18%
2017-12-31	8.58%
2017-09-30	28.61%
2017-06-30	31.20%
2017-03-31	33.55%
2016-12-31	27.55%
2016-09-30	21.56%
2016-06-30	19.24%
2016-03-31	10.94%
2015-12-31	10.97%
2015-09-30	11.77%
2015-06-30	11.84%
2015-03-31	14.49%
2014-12-31	13.49%
2014-09-30	17.94%
2014-06-30	17.54%
2014-03-31	18.68%
2013-12-31	16.91%
2013-09-30	18.76%
2013-06-30	9.46%
2013-03-31	10.75%
2012-12-31	14.39%
2012-09-30	13.58%
2012-06-30	22.16%
2012-03-31	23.41%
2011-12-31	23.25%
2011-09-30	20.15%
2011-06-30	20.30%
2011-03-31	20.91%
2010-12-31	19.74%
2010-09-30	66.65%
2010-06-30	68.04%
2010-03-31	70.28%
2009-12-31	71.49%
2009-09-30	26.39%
2009-06-30	38.61%
2009-03-31	39.17%
2008-12-31	42.86%
2008-09-30	30.25%
2008-06-30	20.36%
2008-03-31	20.23%
2007-12-31	20.50%
2007-09-30	19.01%
2007-06-30	14.87%
2007-03-31	15.21%
2006-12-31	15.86%
2006-09-30	19.14%
2006-06-30	24.28%
2006-03-31	27.53%
2005-12-31	26.77%
2005-09-30	23.43%
2005-06-30	22.53%
2005-03-31	18.85%
2004-12-31	23.41%
2004-09-30	26.56%
2004-06-30	28.57%
2004-03-31	31.85%
2003-12-31	32.21%
2003-09-30	29.24%
2003-06-30	24.90%

DATE

RETURN ON EQUITY (ROE)

2026-06-30

41.59%

2026-03-31

36.25%

2025-12-31

38.19%

2025-09-30

32.55%

2025-06-30

28.96%

2025-03-31

31.16%

2024-12-31

-54.78%

2024-09-30

-42.34%

2024-06-30

-38.44%

2024-03-31

-37.28%

2023-12-31

27.27%

2023-09-30

28.57%

2023-06-30

24.91%

2023-03-31

22.97%

2022-12-31

20.37%

2022-09-30

20.44%

2022-06-30

20.30%

2022-03-31

19.79%

2021-12-31

19.46%

2021-09-30

-14.52%

2021-06-30

-13.80%

2021-03-31

-16.54%

2020-12-31

-23.84%

2020-09-30

-0.09%

2020-06-30

-1.15%

2020-03-31

1.91%

2019-12-31

6.66%

2019-09-30

32.04%

2019-06-30

38.65%

2019-03-31

33.80%

2018-12-31

35.07%

2018-09-30

10.50%

2018-06-30

3.05%

2018-03-31

7.18%

2017-12-31

8.58%

2017-09-30

28.61%

2017-06-30

31.20%

2017-03-31

33.55%

2016-12-31

27.55%

2016-09-30

21.56%

2016-06-30

19.24%

2016-03-31

10.94%

2015-12-31

10.97%

2015-09-30

11.77%

2015-06-30

11.84%

2015-03-31

14.49%

2014-12-31

13.49%

2014-09-30

17.94%

2014-06-30

17.54%

2014-03-31

18.68%

2013-12-31

16.91%

2013-09-30

18.76%

2013-06-30

9.46%

2013-03-31

10.75%

2012-12-31

14.39%

2012-09-30

13.58%

2012-06-30

22.16%

2012-03-31

23.41%

2011-12-31

23.25%

2011-09-30

20.15%

2011-06-30

20.30%

2011-03-31

20.91%

2010-12-31

19.74%

2010-09-30

66.65%

2010-06-30

68.04%

2010-03-31

70.28%

2009-12-31

71.49%

2009-09-30

26.39%

2009-06-30

38.61%

2009-03-31

39.17%

2008-12-31

42.86%

2008-09-30

30.25%

2008-06-30

20.36%

2008-03-31

20.23%

2007-12-31

20.50%

2007-09-30

19.01%

2007-06-30

14.87%

2007-03-31

15.21%

2006-12-31

15.86%

2006-09-30

19.14%

2006-06-30

24.28%

2006-03-31

27.53%

2005-12-31

26.77%

2005-09-30

23.43%

2005-06-30

22.53%

2005-03-31

18.85%

2004-12-31

23.41%

2004-09-30

26.56%

2004-06-30

28.57%

2004-03-31

31.85%

2003-12-31

32.21%

2003-09-30

29.24%

2003-06-30

24.90%

Return on Equity (ROE): 41.59%

BMY Return on Equity (ROE)

BMY Average Return on Equity (ROE) Chart

BMY Current vs Average Return on Equity (ROE) Chart

BMY Return on Equity (ROE) Metrics

BMY Competitors' Return on Equity (ROE)

Return Analysis

Return on Equity (ROE) Formula & Definition

Return on Equity (ROE) FAQ

BMY Return on Equity (ROE) History

Related Metrics